Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Chronic kidney disease
•
Nephrology
•
Endocrinology
Do you offer semaglutide for weight loss management in patients with CKD?
Related Questions
Would you recommend switching a diabetic CKD patient on oral semaglutide to the subcutaneous form since the benefits in CKD have primarily been reported in studies using subcutaneous GLP-1 receptor agonists?
Are you offering GLP-1 agonists to patients with CKD and diabetes mellitus?
Given the cardioprotective and renoprotective effects of SGLT2 inhibitors, should we consider administering to patients with well controlled type 1 diabetes despite the risk of DKA?
Are recurrent UTIs a contraindication to SGLT2i use?
Is there a kidney length for which you would no longer recommend attempting a kidney biopsy due to safety concerns and lack of diagnostic yield?
How do you choose between the different vitamin D analogs for patients with CKD, an elevated PTH, and a normal 25-hydroxy vitamin D level?
Would you recommend oral or intravenous iron in a chronic kidney disease stage 4 patient who is not on an ESA and has a hemoglobin of 12.7 g/dl and an iron saturation of less than 20%?
How do you counsel patients with CKD who are on a PPI given a prior observational study showing an association between PPI use and incident CKD?
Do you avoid ESA use in patients with anemia and chronic kidney disease who also have APLS and risk for thrombosis?
Would you recommend AV fistula placement in a CKD Stage 5 patient who is over the age of 80?
